Allogene Therapeutics (ALLO) Prices 11.7M Share Common Offering at $47/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
June 1, 2020 9:05 PM EDTSOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share. The gross proceeds from this offering are expected to be approximately $550.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about June 4, 2020, subject to customary closing conditions. In addition, Allogene has granted the underwriters a 30-day option to purchase up to 1,755,319 additional... More
